Steris management check
STE · Health Care · Health Care Equipment · CEO Daniel A. Carestio
Filings as of
4 good · 3 to watch · 0 flagged, across the seven questions below.
- Good
Have owners done well?
Beat its chosen peers$100 invested at the start of fiscal 2022 grew to $121, against $107 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.61 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch
What does the CEO cost owners?
1.5% of net income$11.5m of reported pay in fiscal 2026, against $782.3m of net income.
- Watch
Do they own the stock?
CEO stake ≈ 1.3 years of payThe CEO holds 68,075 shares, directly or through trusts (unvested awards not counted): about 1.3 years of pay. 4 insiders sold $2.5m in the last six months and none bought. 3 of 5 sales ran on pre-arranged 10b5-1 plans.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -0.4% a year over the last three fiscal years. Stock-based pay was 1.0% of revenue in the latest year.
- Watch
Is leadership stable?
2 CEOs in the pay tableCEOs in the pay table: Daniel A. Carestio, Walter M Rosebrough. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 67 | 26 | |
| Pay for performance | 81 | 85 | |
| CEO cost | 36 | 44 | |
| Skin in the game | 20 | 46 | |
| Dilution | 54 | 68 | |
| Stable leadership | 60 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Health Care Equipment, by management score. Steris is 37th of 60 in its sector.
- 115ABTAbbott Laboratories75
- 149SYKStryker Corporation72
- 156ISRGIntuitive Surgical72
- 188IDXXIdexx Laboratories69
- 192BSXBoston Scientific69
- 246RVTYRevvity64
- 256GEHCGE HealthCare64
- 294RMDResMed62
- 321STESteris60
- 353BDXBecton Dickinson58
Pay versus performance
From the proxy statement filed June 11, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2026 | Daniel A. Carestio, Walter M Rosebrough | $11.5m | $3.3m | $2.6m | $121 | $107 | $782.3m |
| 2025 | — | $10.7m | $7.9m | $2.6m | $123 | $123 | $614.6m |
| 2024 | — | $9.6m | $14.1m | $2.5m | $120 | $115 | $378.2m |
| 2023 | — | $7.7m | $2.2m | $2.1m | $102 | $99 | $107.0m |
| 2022 | — | $5.9m | $11.8m | $2.4m | $128 | $111 | $243.9m |
The board says pay is tied most to Adjusted EBIT. Its other key measures: Adjusted Free Cash Flow.
Insiders and the CEO's stake
Daniel A Carestio (President and CEO) held 68,075 shares directly after their latest Form 4 on Jun 5, 2026, roughly $14.4m at that filing's price.
4 insiders sold $2.5m in the last six months and none bought. 3 of 5 sales ran on pre-arranged 10b5-1 plans.
- SoldMohsen SohiDirector$957kAug 12, 2026
- SoldDaniel A CarestioPresident and CEO · 10b5-1 plan$947kJun 5, 2026
- SoldRichard C BreedenDirector$310kJun 2, 2026
- SoldJohn Adam ZangerleSr. VP, Gen Counsel, and Sec. · 10b5-1 plan$297kJun 15, 2026
Leadership and governance on file
- Aug 6, 2026Leadership change8-K/A 5.02
- May 7, 2026Leadership change8-K 5.02
- Apr 6, 2026Leadership change8-K 5.02
- Aug 6, 2025Leadership change8-K 5.02
- Jul 3, 2025Leadership change8-K 5.02
- Jul 27, 2023Leadership change8-K/A 5.02
- May 3, 2023Leadership change8-K 5.02
Latest shareholder vote results: Aug 6, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $1.8bn returned to owners in buybacks and dividends, 86% of net income, and $272.2m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.2bn | $4.5bn | $5.1bn | $5.5bn | $5.9bn |
| Net income | $243.9m | $107.0m | $378.2m | $614.6m | $782.3m |
| Stock-based pay | $57.7m | $39.0m | $56.5m | $57.4m | $61.7m |
| Buybacks | $55.8m | $308.6m | $11.8m | $211.3m | $235.5m |
| Dividends | $163.2m | $183.5m | $200.6m | $219.9m | $241.8m |
| Diluted shares | 98m | 100m | 99m | 99m | 99m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.